ECSP17015977A - Terapia de combinacion - Google Patents
Terapia de combinacionInfo
- Publication number
- ECSP17015977A ECSP17015977A ECIEPI201715977A ECPI201715977A ECSP17015977A EC SP17015977 A ECSP17015977 A EC SP17015977A EC IEPI201715977 A ECIEPI201715977 A EC IEPI201715977A EC PI201715977 A ECPI201715977 A EC PI201715977A EC SP17015977 A ECSP17015977 A EC SP17015977A
- Authority
- EC
- Ecuador
- Prior art keywords
- combination therapy
- therapy
- combination
- attached
- summary attached
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Massaging Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE ADJUNTA RESUMEN
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050967P | 2014-09-16 | 2014-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17015977A true ECSP17015977A (es) | 2018-03-31 |
Family
ID=54207720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201715977A ECSP17015977A (es) | 2014-09-16 | 2017-03-15 | Terapia de combinacion |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9999624B2 (es) |
| EP (1) | EP3193882A1 (es) |
| JP (1) | JP6339741B2 (es) |
| KR (1) | KR101871128B1 (es) |
| CN (1) | CN106687136A (es) |
| AP (1) | AP2017009794A0 (es) |
| AR (1) | AR101740A1 (es) |
| AU (1) | AU2015318257B2 (es) |
| BR (1) | BR112017003571A2 (es) |
| CA (1) | CA2956835A1 (es) |
| CL (1) | CL2017000558A1 (es) |
| CO (1) | CO2017001875A2 (es) |
| CR (1) | CR20170080A (es) |
| DO (1) | DOP2017000071A (es) |
| EA (1) | EA031764B1 (es) |
| EC (1) | ECSP17015977A (es) |
| IL (1) | IL250387A0 (es) |
| MX (1) | MX2017003414A (es) |
| NZ (1) | NZ728636A (es) |
| PE (1) | PE20170464A1 (es) |
| PH (1) | PH12017500493A1 (es) |
| SG (1) | SG11201701330PA (es) |
| SV (1) | SV2017005389A (es) |
| TN (1) | TN2017000072A1 (es) |
| TW (1) | TWI599358B (es) |
| WO (1) | WO2016043997A1 (es) |
| ZA (1) | ZA201700826B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201742625A (zh) * | 2016-03-15 | 2017-12-16 | 阿斯特捷利康公司 | 組合療法 |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| CN109641052A (zh) * | 2016-08-18 | 2019-04-16 | 伊莱利利公司 | BACE-1抑制剂和抗-N3pGlu Aβ抗体的组合疗法 |
| TWI669119B (zh) * | 2016-10-21 | 2019-08-21 | 美國禮來大藥廠 | 組合療法 |
| KR20190077349A (ko) | 2016-10-28 | 2019-07-03 | 하. 룬드벡 아크티에셀스카브 | 이미다조피라지논의 투여를 포함하는 병용 치료 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| RS62551B1 (sr) | 2017-12-14 | 2021-12-31 | H Lundbeck As | Kombinovane terapije koje obuhvataju primenu 1h-pirazolo[4,3-b]piridina |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| EP3728250A1 (en) | 2017-12-20 | 2020-10-28 | H. Lundbeck A/S | PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS |
| US10350226B1 (en) | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
| US12350278B2 (en) | 2018-06-27 | 2025-07-08 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections in non-human animals |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| US20230236199A1 (en) * | 2020-04-23 | 2023-07-27 | Eli Lilly And Company | Subcutaneous absorption and bioavailability of antibodies |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
| WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE424383T1 (de) | 2003-08-08 | 2009-03-15 | Schering Corp | Cyclische amine mit benzamidsubstituent als bace- 1-inhibitoren |
| BRPI0906962B8 (pt) * | 2008-01-18 | 2021-05-25 | Eisai R&D Man Co Ltd | composto de aminodiidrotiazina fundido |
| LT3339323T (lt) * | 2010-08-12 | 2020-02-10 | Eli Lilly And Company | Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| TWI593692B (zh) * | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
-
2015
- 2015-09-01 TW TW104128851A patent/TWI599358B/zh not_active IP Right Cessation
- 2015-09-02 AR ARP150102803A patent/AR101740A1/es unknown
- 2015-09-08 EA EA201790305A patent/EA031764B1/ru not_active IP Right Cessation
- 2015-09-08 EP EP15771800.8A patent/EP3193882A1/en not_active Withdrawn
- 2015-09-08 KR KR1020177006748A patent/KR101871128B1/ko not_active Expired - Fee Related
- 2015-09-08 CA CA2956835A patent/CA2956835A1/en not_active Abandoned
- 2015-09-08 SG SG11201701330PA patent/SG11201701330PA/en unknown
- 2015-09-08 TN TN2017000072A patent/TN2017000072A1/en unknown
- 2015-09-08 NZ NZ728636A patent/NZ728636A/en not_active IP Right Cessation
- 2015-09-08 CR CR20170080A patent/CR20170080A/es unknown
- 2015-09-08 AU AU2015318257A patent/AU2015318257B2/en not_active Ceased
- 2015-09-08 PE PE2017000406A patent/PE20170464A1/es unknown
- 2015-09-08 MX MX2017003414A patent/MX2017003414A/es unknown
- 2015-09-08 US US15/503,027 patent/US9999624B2/en not_active Expired - Fee Related
- 2015-09-08 BR BR112017003571A patent/BR112017003571A2/pt not_active Application Discontinuation
- 2015-09-08 CN CN201580049574.0A patent/CN106687136A/zh active Pending
- 2015-09-08 AP AP2017009794A patent/AP2017009794A0/en unknown
- 2015-09-08 WO PCT/US2015/048807 patent/WO2016043997A1/en not_active Ceased
- 2015-09-08 JP JP2017514623A patent/JP6339741B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-01 IL IL250387A patent/IL250387A0/en unknown
- 2017-02-02 ZA ZA2017/00826A patent/ZA201700826B/en unknown
- 2017-02-22 SV SV2017005389A patent/SV2017005389A/es unknown
- 2017-02-24 CO CONC2017/0001875A patent/CO2017001875A2/es unknown
- 2017-03-08 CL CL2017000558A patent/CL2017000558A1/es unknown
- 2017-03-14 DO DO2017000071A patent/DOP2017000071A/es unknown
- 2017-03-15 PH PH12017500493A patent/PH12017500493A1/en unknown
- 2017-03-15 EC ECIEPI201715977A patent/ECSP17015977A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2017009794A0 (en) | 2017-03-31 |
| US9999624B2 (en) | 2018-06-19 |
| TWI599358B (zh) | 2017-09-21 |
| IL250387A0 (en) | 2017-03-30 |
| PH12017500493A1 (en) | 2017-08-07 |
| CN106687136A (zh) | 2017-05-17 |
| AR101740A1 (es) | 2017-01-11 |
| CA2956835A1 (en) | 2016-03-24 |
| EP3193882A1 (en) | 2017-07-26 |
| EA201790305A1 (ru) | 2017-07-31 |
| KR101871128B1 (ko) | 2018-06-25 |
| SV2017005389A (es) | 2018-01-17 |
| TW201618786A (zh) | 2016-06-01 |
| CR20170080A (es) | 2017-03-30 |
| EA031764B1 (ru) | 2019-02-28 |
| JP2017529348A (ja) | 2017-10-05 |
| CL2017000558A1 (es) | 2017-11-10 |
| TN2017000072A1 (en) | 2018-07-04 |
| DOP2017000071A (es) | 2017-06-15 |
| AU2015318257A1 (en) | 2017-02-16 |
| ZA201700826B (en) | 2018-12-19 |
| WO2016043997A1 (en) | 2016-03-24 |
| NZ728636A (en) | 2018-05-25 |
| CO2017001875A2 (es) | 2017-05-19 |
| PE20170464A1 (es) | 2017-04-26 |
| AU2015318257B2 (en) | 2018-06-14 |
| MX2017003414A (es) | 2017-06-19 |
| US20170224702A1 (en) | 2017-08-10 |
| BR112017003571A2 (pt) | 2017-12-19 |
| SG11201701330PA (en) | 2017-04-27 |
| JP6339741B2 (ja) | 2018-06-06 |
| KR20170036103A (ko) | 2017-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17015977A (es) | Terapia de combinacion | |
| ECSP17029371A (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| EP3463464A4 (en) | ASSOCIATION TREATMENT | |
| GEAP202114450A (en) | Anti-tigit antibodies | |
| DK3240801T3 (da) | Kombinationstumorimmunterapi | |
| DK3209778T3 (da) | Kombination | |
| HUE054012T2 (hu) | Kombinációs terápia rák ellen | |
| DK3169292T3 (da) | Urinadsorberende tampon | |
| TWD174683S (zh) | 戒指 | |
| DK3171891T3 (da) | Fremgangsmåde | |
| DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
| DK3612624T3 (da) | Genterapi | |
| EP3360010A4 (en) | BI PHOTONS WITH VOTABLE SOURCE | |
| DK3215607T3 (da) | Phagterapi | |
| IN2015DE00625A (es) | ||
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| EP3512553A4 (en) | KLRG1 EXHAUST THERAPY | |
| IL262851A (en) | Combination prime: boost therapy | |
| ECSP17014972A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| MA40836A (fr) | Procédures de semi-synthèse | |
| MY167383A (en) | Disposable diaper | |
| DE112015001144A5 (de) | Therapievorrichtung | |
| GEAP201814327A (en) | Treatment regimen tiacumicin compound |